Business
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Mily will be leading the company strategy and all business development activities. This includes overseeing strategic partnerships, mergers and acquisitions, etc.
The company did not know of her intention to leave the U.S. for China. They did not know she had been gone until the Chinese media reported the story. She was terminated by Biogen this week.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
Companies strengthen their leadership teams and board with this week’s Movers & Shakers.
Epidemiologists believe COVID-19 will likely affect millions of people in the U.S. If early prevention efforts are not made Swine Flu Pandemic of 2009.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
OncoOne currently has three drug candidates for four indications (colorectal, pancreatic, ovarian and lung cancers).
For nearly 30 years, Richard Miller has been at the forefront of developing treatments for lymphomas, most notably the multi-billion dollar breakthroughs Rituxan and Imbruvica. In recognition of his decades of work, Miller was awarded with the 2020 Drug Hunter Award.
Researchers found fear of testing new treatments and possible side effects were common denominators among patients.
Approximately 100 cases of COVID-19 have been linked to a Biogen corporate meeting, as reported by a local media station in the Boston area.